The miRNA Pull Out Assay as a Method to Validate the miR-28-5p Targets Identified in Other Tumor Contexts in Prostate Cancer

miR-28-5p is an intragenic miRNA which is underexpressed in several tumor types showing a tumor suppressor (TS) activity. Routinely, the known miR-28-5p targets are validated in specific tumor contexts but it is unclear whether these targets are also being regulated in other tumor types. To this end...

Full description

Bibliographic Details
Main Authors: Milena Rizzo, Gabriele Berti, Francesco Russo, Monica Evangelista, Marco Pellegrini, Giuseppe Rainaldi
Format: Article
Language:English
Published: Hindawi Limited 2017-01-01
Series:International Journal of Genomics
Online Access:http://dx.doi.org/10.1155/2017/5214806
id doaj-27541680fe694539a26070cbfa0bd0f5
record_format Article
spelling doaj-27541680fe694539a26070cbfa0bd0f52020-11-24T22:02:27ZengHindawi LimitedInternational Journal of Genomics2314-436X2314-43782017-01-01201710.1155/2017/52148065214806The miRNA Pull Out Assay as a Method to Validate the miR-28-5p Targets Identified in Other Tumor Contexts in Prostate CancerMilena Rizzo0Gabriele Berti1Francesco Russo2Monica Evangelista3Marco Pellegrini4Giuseppe Rainaldi5Non-coding RNA Laboratory, Institute of Clinical Physiology (IFC), CNR, Via Moruzzi 1, 56124 Pisa, ItalyNon-coding RNA Laboratory, Institute of Clinical Physiology (IFC), CNR, Via Moruzzi 1, 56124 Pisa, ItalyLaboratory of Integrative Systems Medicine (LISM), Institute of Informatics and Telematics (IIT) and Institute of Clinical Physiology (IFC), CNR, Via Moruzzi 1, 56124 Pisa, ItalyNon-coding RNA Laboratory, Institute of Clinical Physiology (IFC), CNR, Via Moruzzi 1, 56124 Pisa, ItalyLaboratory of Integrative Systems Medicine (LISM), Institute of Informatics and Telematics (IIT) and Institute of Clinical Physiology (IFC), CNR, Via Moruzzi 1, 56124 Pisa, ItalyNon-coding RNA Laboratory, Institute of Clinical Physiology (IFC), CNR, Via Moruzzi 1, 56124 Pisa, ItalymiR-28-5p is an intragenic miRNA which is underexpressed in several tumor types showing a tumor suppressor (TS) activity. Routinely, the known miR-28-5p targets are validated in specific tumor contexts but it is unclear whether these targets are also being regulated in other tumor types. To this end, we adopted the miRNA pull out assay to capture the miR-28-5p targets in DU-145 prostate cancer (PCa) cells. Firstly, we demonstrated that miR-28-5p acts as a TS-miRNA in PCa, affecting cell proliferation, survival, and apoptosis. Secondly, we evaluated the enrichment of the 10 validated miR-28-5p targets in the pull out sample. We showed that E2F6, TEX-261, MAPK1, MPL, N4BP1, and RAP1B but not BAG1, OTUB1, MAD2L1, and p21 were significantly enriched, suggesting that not all the miR-28-5p targets are regulated by this miRNA in PCa. We then verified whether the miR-28-5p-interacting targets were regulated by this miRNA. We selected E2F6, the most enriched target in the pull out sample, and demonstrated that miR-28-5p downregulated E2F6 at the protein level suggesting that our approach was effective. In general terms, these findings support the miRNA pull out assay as a useful method to identify context-specific miRNA targets.http://dx.doi.org/10.1155/2017/5214806
collection DOAJ
language English
format Article
sources DOAJ
author Milena Rizzo
Gabriele Berti
Francesco Russo
Monica Evangelista
Marco Pellegrini
Giuseppe Rainaldi
spellingShingle Milena Rizzo
Gabriele Berti
Francesco Russo
Monica Evangelista
Marco Pellegrini
Giuseppe Rainaldi
The miRNA Pull Out Assay as a Method to Validate the miR-28-5p Targets Identified in Other Tumor Contexts in Prostate Cancer
International Journal of Genomics
author_facet Milena Rizzo
Gabriele Berti
Francesco Russo
Monica Evangelista
Marco Pellegrini
Giuseppe Rainaldi
author_sort Milena Rizzo
title The miRNA Pull Out Assay as a Method to Validate the miR-28-5p Targets Identified in Other Tumor Contexts in Prostate Cancer
title_short The miRNA Pull Out Assay as a Method to Validate the miR-28-5p Targets Identified in Other Tumor Contexts in Prostate Cancer
title_full The miRNA Pull Out Assay as a Method to Validate the miR-28-5p Targets Identified in Other Tumor Contexts in Prostate Cancer
title_fullStr The miRNA Pull Out Assay as a Method to Validate the miR-28-5p Targets Identified in Other Tumor Contexts in Prostate Cancer
title_full_unstemmed The miRNA Pull Out Assay as a Method to Validate the miR-28-5p Targets Identified in Other Tumor Contexts in Prostate Cancer
title_sort mirna pull out assay as a method to validate the mir-28-5p targets identified in other tumor contexts in prostate cancer
publisher Hindawi Limited
series International Journal of Genomics
issn 2314-436X
2314-4378
publishDate 2017-01-01
description miR-28-5p is an intragenic miRNA which is underexpressed in several tumor types showing a tumor suppressor (TS) activity. Routinely, the known miR-28-5p targets are validated in specific tumor contexts but it is unclear whether these targets are also being regulated in other tumor types. To this end, we adopted the miRNA pull out assay to capture the miR-28-5p targets in DU-145 prostate cancer (PCa) cells. Firstly, we demonstrated that miR-28-5p acts as a TS-miRNA in PCa, affecting cell proliferation, survival, and apoptosis. Secondly, we evaluated the enrichment of the 10 validated miR-28-5p targets in the pull out sample. We showed that E2F6, TEX-261, MAPK1, MPL, N4BP1, and RAP1B but not BAG1, OTUB1, MAD2L1, and p21 were significantly enriched, suggesting that not all the miR-28-5p targets are regulated by this miRNA in PCa. We then verified whether the miR-28-5p-interacting targets were regulated by this miRNA. We selected E2F6, the most enriched target in the pull out sample, and demonstrated that miR-28-5p downregulated E2F6 at the protein level suggesting that our approach was effective. In general terms, these findings support the miRNA pull out assay as a useful method to identify context-specific miRNA targets.
url http://dx.doi.org/10.1155/2017/5214806
work_keys_str_mv AT milenarizzo themirnapulloutassayasamethodtovalidatethemir285ptargetsidentifiedinothertumorcontextsinprostatecancer
AT gabrieleberti themirnapulloutassayasamethodtovalidatethemir285ptargetsidentifiedinothertumorcontextsinprostatecancer
AT francescorusso themirnapulloutassayasamethodtovalidatethemir285ptargetsidentifiedinothertumorcontextsinprostatecancer
AT monicaevangelista themirnapulloutassayasamethodtovalidatethemir285ptargetsidentifiedinothertumorcontextsinprostatecancer
AT marcopellegrini themirnapulloutassayasamethodtovalidatethemir285ptargetsidentifiedinothertumorcontextsinprostatecancer
AT giusepperainaldi themirnapulloutassayasamethodtovalidatethemir285ptargetsidentifiedinothertumorcontextsinprostatecancer
AT milenarizzo mirnapulloutassayasamethodtovalidatethemir285ptargetsidentifiedinothertumorcontextsinprostatecancer
AT gabrieleberti mirnapulloutassayasamethodtovalidatethemir285ptargetsidentifiedinothertumorcontextsinprostatecancer
AT francescorusso mirnapulloutassayasamethodtovalidatethemir285ptargetsidentifiedinothertumorcontextsinprostatecancer
AT monicaevangelista mirnapulloutassayasamethodtovalidatethemir285ptargetsidentifiedinothertumorcontextsinprostatecancer
AT marcopellegrini mirnapulloutassayasamethodtovalidatethemir285ptargetsidentifiedinothertumorcontextsinprostatecancer
AT giusepperainaldi mirnapulloutassayasamethodtovalidatethemir285ptargetsidentifiedinothertumorcontextsinprostatecancer
_version_ 1725835718367903744